“Bimekizumab Response Maintenance through Two Years of Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Responded After 16 Weeks: Interim Results from the BE BRIGHT Open-Label Extension Trial”. 2021. SKIN The Journal of Cutaneous Medicine 5 (6): s52. https://doi.org/10.25251/skin.5.supp.52.